Tuesday, May 2nd, 2017, 4:30 pm - 5:20 pm

Location: Boston Scientific Ballroom

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.

Disruptive Therapeutic Platforms: New Tools, New Outcomes

Tuesday, May 2nd, 2017, 4:30 pm - 5:20 pm

Location: Boston Scientific Ballroom

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.